Cleveland Clinic
Cleveland, Ohio, United States
155 recruiting
Showing 1–20 of 416 trials
Recruiting
Phase 3
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Ductal Adenocarcinoma (PDAC)
SOFIE200 enrolled15 locationsNCT07217717
Recruiting
Phase 3
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled15 locationsNCT07217704
Recruiting
Not Applicable
Alleviant ALLAY-HFrEF Study
Heart Failure
Alleviant Medical, Inc.350 enrolledNCT06812533
Recruiting
Phase 3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Chronic Kidney Disease
Boehringer Ingelheim120 enrolled102 locationsNCT07107945
Recruiting
Not Applicable
The Fourth Left Atrial Appendage Occlusion Study
Atrial FibrillationStroke, IschemicSystemic Embolism
Hamilton Health Sciences Corporation4,000 enrolled140 locationsNCT05963698
Recruiting
Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
Membranous NephropathyNephrotic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)58 enrolled20 locationsNCT03949855
Recruiting
Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (CSCC)
Regeneron Pharmaceuticals369 enrolled52 locationsNCT06585410
Recruiting
Not Applicable
I-Score: Intensive Stroke Cycling for Optimal Recovery and Economic Value
Stroke
The Cleveland Clinic66 enrolled1 locationNCT06585943
Recruiting
Phase 1Phase 2
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled28 locationsNCT05320198
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled141 locationsNCT06615479
Recruiting
Phase 3
Pridopidine Phase 3 Study in Huntington's Disease
Huntington Disease
Prilenia400 enrolledNCT07609108
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting
Phase 2
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Adjustment Disorder
Reunion Neuroscience Inc100 enrolled30 locationsNCT07002034
Recruiting
Not Applicable
Exercise Training Decreases Alcohol Consumption and Tissue Injury by an FGF21-dependent Mechanism
Alcohol-related Liver DiseaseAlcohol Use Disorder (AUD)
The Cleveland Clinic30 enrolledNCT07824089
Recruiting
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
Tricuspid Regurgitation
Montefiore Medical Center800 enrolled21 locationsNCT06033274
Recruiting
Phase 1Phase 2
Safety of HRX215 in Patients After Minor and Major Liver Resection
Liver ResectionColorectal Carcinoma Liver Metastases
HepaRegeniX GmbH80 enrolled12 locationsNCT06638502
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled555 locationsNCT06492616
Recruiting
Phase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Dravet Syndrome
Epygenix150 enrolled60 locationsNCT04462770
Recruiting
Phase 3
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Uveal Melanoma
IDEAYA Biosciences450 enrolledNCT07804186
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb474 enrolled91 locationsNCT07293351